Net earnings grew over 18% to $5.5 billion, or $2.29 per share, compared to last year. Adjusted EPS dropped 1.8% to $2.77.
Revenue and earnings beat expectations.
The company saw sales in the US increase 7.8% to $13.5 billion while international sales grew 3.2% to $10.2 billion.
ADVERTISEMENT
Sales in the Innovative Medicine segment rose 4.9% to $15.2 billion while sales in the MedTech segment increased 7.3% to $8.5 billion.
For full-year 2025, JNJ expects reported sales to range between $93.2-93.6 billion while adjusted EPS is expected to be $10.80-10.90.
The stock gained 2% in premarket hours on Wednesday.